Danco Laboratories, the sole manufacturer of the abortion drug mifepristone, filed an emergency request with the Supreme Court on May 2 seeking to block an appeals court ruling that would force women to visit a doctor in person before obtaining the pill by mail. The move came just one day after a three-judge panel on the Fifth Circuit Court of Appeals reinstated an FDA requirement the Biden administration had eliminated, a requirement that Louisiana argued was the only thing standing between its abortion laws and roughly a thousand illegal abortions each month.
The case lands on the justices' desks two years after they tossed out a similar challenge to mifepristone access. But this time the challenger is not a group of anti-abortion doctors. It is a state, Louisiana, and the legal terrain has shifted beneath everyone's feet.
Mifepristone is used in nearly two-thirds of all abortions performed in the United States. How the Court handles this emergency filing will shape whether mail-order abortion pills remain the dominant method of ending pregnancies nationwide, or whether states that have restricted abortion can actually enforce their own laws.
On May 1, the conservative Fifth U.S. Circuit Court of Appeals temporarily reinstated an FDA rule requiring doctors to examine patients in person before prescribing mifepristone. The Biden administration had scrapped that requirement, opening the door for the drug to be prescribed via telehealth and shipped through the mail, even into states where abortion is banned or heavily restricted.
Louisiana challenged that rollback directly. The state's argument was blunt: allowing mifepristone to travel by mail ignores the threat of medical complications and lets women circumvent state abortion bans. The Fifth Circuit panel agreed, at least for now, writing that the looser dispensing rule "facilitates nearly 1,000 illegal abortions in Louisiana per month."
That number deserves attention. If accurate, it means a single federal regulatory change, made without a vote in Congress, effectively nullified Louisiana's abortion restrictions for hundreds of women every week. For voters who believe the Dobbs decision returned abortion policy to the states, the Fifth Circuit's finding is a reminder that federal agencies can still undercut state law with the stroke of a pen.
The appeals court also blocked a lower federal judge's earlier ruling. In January, the administration had asked that judge to pause Louisiana's challenge until the Trump administration's FDA could finish its own safety review of mifepristone. The judge agreed. But the Fifth Circuit reversed course, saying the in-person dispensing requirement should snap back into place while Louisiana's appeal moves forward.
Danco wasted no time. In its May 2 filing, the company told the Supreme Court that Louisiana's lawsuit suffers from the same defects as the earlier challenge brought by anti-abortion doctors, a case the justices rejected in 2024 on standing grounds, ruling that the doctors lacked a legitimate basis to challenge the FDA's decisions.
Lawyers for Danco framed the Fifth Circuit's action in sweeping terms:
"Never before has a federal court purported to immediately enjoin a several years' old drug approval; restrict a distribution system for that drug that manufacturers, providers, patients, and pharmacies have all been using for years; or reinstate conditions that FDA determined do not meet the mandatory statutory criteria."
The company also argued that the ruling "injects immediate confusion and upheaval into highly time-sensitive medical decisions." The filing asked the Court to act quickly, the same kind of emergency intervention the justices granted in 2023, when they paused a ruling from the very same appeals court that would have reimposed the in-person requirement during the doctors' lawsuit.
That 2023 Supreme Court stay kept mifepristone available nationwide while litigation continued. At the time, only Justices Samuel Alito and Clarence Thomas indicated they would have let the lower-court restrictions stand. The Biden administration and Danco had both urged the Court to intervene, warning that the lower-court rulings would be "highly disruptive" to drug access and federal regulation.
Danco's core legal argument is that Louisiana's complaint "should have been dismissed outright." The company believes the state, like the anti-abortion doctors before it, cannot show the kind of direct injury required to challenge FDA regulatory decisions in federal court.
But Louisiana may have a stronger standing claim than the doctors did. A state enforcing its own criminal abortion statute has a more direct stake in whether a federal agency's rule effectively overrides that statute. The Supreme Court has shown increasing willingness to side with states asserting their sovereign interests against federal overreach, and the Fifth Circuit clearly found Louisiana's argument persuasive enough to act.
The justices' 2024 ruling against the anti-abortion doctors turned on standing, not on the merits of mifepristone regulation. That means the underlying question, whether the FDA acted lawfully when it loosened prescribing rules, has never been resolved. Louisiana's lawsuit forces the Court to confront it, possibly for the first time.
Complicating the picture further, the Trump administration's FDA is conducting its own safety review of mifepristone. The administration itself asked a federal judge in January to hit pause on Louisiana's challenge until that review wraps up. The judge obliged, but the Fifth Circuit overruled him.
The scope and timeline of the FDA review remain unclear. What is clear is that the administration wanted a breather, time to let its own scientists weigh in before the courts locked in a result. The Fifth Circuit denied that request, effectively telling both the state and the federal government that the in-person requirement should be restored now, not after a bureaucratic review of uncertain duration.
For pro-life advocates, the FDA review is a double-edged sword. If the agency ultimately concludes that mifepristone's loosened rules were scientifically justified, it becomes much harder for states like Louisiana to argue otherwise. If the review finds safety concerns, it strengthens the case for tighter controls, but it also means the Trump administration's own agency would be validating the restrictions.
The high-stakes maneuvering at the Supreme Court this term reflects a broader pattern: the justices are being asked to referee an escalating series of conflicts between federal regulatory power and the rights of states and citizens to govern themselves.
Nancy Northup, head of the Center for Reproductive Rights, issued a statement casting the FDA review and the legal challenges in purely political terms:
"This isn't about science. It's about making abortion as difficult, expensive, and unreachable as possible."
That framing is predictable, but it sidesteps the actual legal question. Louisiana is not arguing that mifepristone should be banned nationwide. It is arguing that a federal agency cannot unilaterally erase the regulatory safeguards that allowed states to enforce their own abortion laws. Whether you call that "science" or "federalism" depends on where you sit, but the Constitution does have something to say about who gets to make these decisions.
The pattern of progressive groups framing every adverse court ruling as illegitimate has become routine. When the Court rules their way, it is the rule of law. When it does not, it is politics masquerading as jurisprudence.
The Supreme Court now faces a familiar choice. It can grant Danco's emergency request and restore the status quo, mail-order mifepristone, no in-person visit required, while the legal fight continues. Or it can let the Fifth Circuit's order stand, forcing providers and patients to comply with the reinstated in-person requirement immediately.
In 2023, the Court chose the first option. But the composition of the argument has changed. Louisiana is a sovereign state, not a private group of physicians. The Trump administration's own FDA is mid-review. And the political landscape around abortion has only grown more charged since Dobbs.
The Court's recent willingness to uphold state authority in contested areas suggests the justices may not be as quick to intervene this time. But emergency applications move fast, and the Court's internal dynamics are difficult to predict from the outside.
What is not in doubt is the stakes. Nearly two-thirds of abortions in America involve mifepristone. If the mail-order pipeline stays open, state abortion restrictions in places like Louisiana are, in practice, unenforceable for any woman with internet access and a mailbox. If the in-person requirement returns, states regain at least some ability to apply the laws their legislatures passed and their voters approved.
The Dobbs decision promised that abortion policy would return to the people and their elected representatives. Whether that promise means anything depends on whether a federal agency can quietly hand it back.
